Dr. Gabriel Cohn joined RFRF in October 2022 and serves as both Executive Director and Medical Director. Dr. Cohn is a licensed, board-certified Clinical Geneticist and Obstetrician Gynecologist with more than 30 years of experience in academic medicine and the biotechnology industry and has contributed to the development of multiple therapeutics for the treatment of rare genetic disorders.
In addition to his role at RFRF, he serves as the Chief Medical Officer (CMO) at iECURE, Inc., a biotech company focused on developing gene editing therapies for rare genetic diseases. He previously served as the CMO of Homology Medicines where he led the company’s Phase 1/2 gene therapy and gene editing clinical programs in PKU and MPSII. Prior to that, Gabe was Vice President of Clinical Development at AVROBIO, where he led the ex-vivo gene therapy program for Gaucher disease and Pompe disease, and had served in various executive leadership roles at OvaScience and Shire. Since 2017, he has supported and led the successful IND and CTA submissions across five different cell and gene therapy indications and platforms.
He is a Fellow of the American College of Genetics and Genomics (ACMG) and the American College of Obstetrics and Gynecology (ACOG), author of more than 40 peer-reviewed publications and chapters and served as the Chief of Clinical and Reproductive Genetics and Medical Director, Genetic Services at Baystate Medical Center and as Assistant Professor at Tufts University School of Medicine. He earned his M.D. from SUNY Health Science Center at Syracuse and MBA from the Isenberg School of Management at the University of Massachusetts Amherst. Amherst, MA. He completed a residency in Obstetrics & Gynecology at SUNY HSC at Syracuse, NY and a fellowship in Medical Genetics at the National Institutes of Health in Bethesda, MD.